# APC8015 and Bevacizumab in Treating Patients With Prostate Cancer

> **NCT00027599** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **BIOLOGICAL:** bevacizumab
- **BIOLOGICAL:** prostatic acid phosphatase-sargramostim fusion protein
- **BIOLOGICAL:** sipuleucel-T
- **BIOLOGICAL:** therapeutic autologous dendritic cells
- **PROCEDURE:** in vitro-treated peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00027599
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2013-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00027599

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00027599, "APC8015 and Bevacizumab in Treating Patients With Prostate Cancer". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00027599. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*